The spread between the cheapest and most expensive listing for the same compound is often large enough to look like an error. Sometimes it is a margin difference. More often it reflects a real difference in what is in the vial and what was done to establish that.
Chain length is the first driver
Each additional residue is another synthesis cycle, and losses compound multiplicatively. A ten-residue peptide at 99% coupling efficiency finishes near 90% of theoretical before purification; a forty-residue chain finishes closer to 67%, and lower efficiency makes that worse quickly.
Lower crude yield means more input material per gram of finished product, and more complex crude means harder purification with more loss at that stage too. This is most of why a three-residue compound and a forty-residue one are not in the same price bracket.
Difficult sequences cost more than their length suggests
Length is not the whole story. Sequences prone to aggregating on the resin resist coupling at specific positions, and the responses — double couplings, elevated temperature, specialised building blocks — all add cost. A short difficult peptide can cost more to make than a longer straightforward one.
Non-standard residues raise cost independently. A sequence requiring unusual protected building blocks, a cyclisation step or a fatty-acid acylation carries the price of those inputs and operations.
Purity costs yield
Taking a lot from 95% to 99% is not a small extra step. In preparative chromatography, higher purity means collecting a narrower window around the main peak and discarding more material that is partly product. The purer specification is reached by throwing more away.
This is a genuine and often invisible difference between two quotes. A supplier releasing at 98% and one releasing at 99.5% are selling different products, and the second has lower yield per batch by design.
Analysis is a real line item
A full panel costs money per lot. HPLC purity, mass spectrometry identity, endotoxin, sterility, elemental impurities, residual solvents and water content are separate determinations, some of them sent to an outside accredited laboratory.
A supplier running identity and purity in-house and nothing else has a materially lower cost per lot than one running a full panel with third-party confirmation. That gap shows up in price, and it is the single most common reason a cheap listing is cheap.
Volume and the parts that do not scale
Testing, documentation and setup are largely fixed per lot rather than per gram, which is why larger lots price better per unit: the same analytical cost spreads across more material.
That is the legitimate basis for wholesale pricing, and it is also the reason a very small order of a rarely requested compound can look disproportionately expensive. The fixed costs have nowhere to spread.
Comparing two quotes honestly
- Compare on net peptide content, not vial weight. Two 10 mg vials at different net content are different quantities of compound.
- Compare the analytical scope. Ask which tests are included per lot and which are in-house versus external.
- Compare the released specification, not the marketing figure. A 99% claim and a ≥99% release specification with lot-specific results are different commitments.
- Account for shipping conditions, since temperature-controlled transport is a real cost that some quotes include and others add.
A price gap that survives all four comparisons may simply be margin. One that does not survive them was never a like-for-like comparison.
This is one part of buying wholesale. Wholesale peptides for clinics covers the whole process from evaluating a supplier to placing a first order.